Passage Bio, Inc., a genetic medicines company, focuses on developing transformative therapies for rare monogenic central nervous system (CNS) diseases. It has research, collaboration, and license agreement with the University of Pennsylvania and its gene therapy program; and The Trustees of the University of Pennsylvania for research and development collaborations, and exclusive license rights to patents for certain products and technologies. The company was founded in 2017 and is based in Philadelphia, Pennsylvania.
cash 情况：366M，可以跑5个季度（？）
产品：无
上市：今年大崩溃前。
现在情况：六月底到顶后连续下降（表面没有原因），至少三天没有往下走了。主观判断：可能小反弹。（笑翻天）
昨天没有管住手，买了几股。（下定决心再也不买了。Really？）
PS：“G & G 妈” 网友昨天也说了这个股票。
